Litcius/Paper detail

Molecular Basis of Resveratrol-Induced Resensitization of Acquired Drug-Resistant Cancer Cells

Chul Yung Choi, Sung‐Chul Lim, Tae-Bum Lee, Song Iy Han

2022Nutrients34 citationsDOIOpen Access PDF

Abstract

Multidrug resistance (MDR) to anticancer drugs remains a serious obstacle to the success of cancer chemotherapy. Resveratrol, a polyphenol, present in natural products exerts anticancer activity and acts as a potential MDR inhibitor in various drug-resistant cancer cells. In the process of resensitization of drug-resistant cancer cells, resveratrol has been shown to interfere with ABC transporters and drug-metabolizing enzymes, increase DNA damage, inhibit cell cycle progression, and induce apoptosis and autophagy, as well as prevent the induction of epithelial to mesenchymal transition (EMT) and cancer stem cells (CSCs). This review summarizes the mechanisms by which resveratrol counteracts MDR in acquired drug-resistant cancer cell lines and provides a critical basis for understanding the regulation of MDR as well as the development of MDR-inhibiting drugs.

Topics & Concepts

ResveratrolMultiple drug resistanceCancer cellCancer stem cellAutophagyCancerCancer researchDrug resistanceBiologyApoptosisCell cyclePharmacologyBiochemistryMicrobiologyGeneticsRNA modifications and cancerHistone Deacetylase Inhibitors ResearchSirtuins and Resveratrol in Medicine
Molecular Basis of Resveratrol-Induced Resensitization of Acquired Drug-Resistant Cancer Cells | Litcius